vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.

PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $267.3M, roughly 1.4× Ascendis Pharma A/S). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 19.2%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...

ASND vs PB — Head-to-Head

Bigger by revenue
PB
PB
1.4× larger
PB
$367.6M
$267.3M
ASND
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
19.2%
PB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASND
ASND
PB
PB
Revenue
$267.3M
$367.6M
Net Profit
$116.3M
Gross Margin
90.5%
Operating Margin
Net Margin
31.6%
Revenue YoY
42.3%
Net Profit YoY
-10.7%
EPS (diluted)
$1.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
PB
PB
Q1 26
$367.6M
Q4 25
$267.3M
$275.0M
Q3 25
$230.7M
$273.4M
Q2 25
$170.7M
$267.7M
Q1 25
$109.0M
$265.4M
Q4 24
$187.8M
$267.8M
Q3 24
$62.5M
$261.7M
Q2 24
$38.9M
$258.8M
Net Profit
ASND
ASND
PB
PB
Q1 26
$116.3M
Q4 25
$139.9M
Q3 25
$-65.9M
$137.6M
Q2 25
$-42.0M
$135.2M
Q1 25
$-102.2M
$130.2M
Q4 24
$130.1M
Q3 24
$-107.1M
$127.3M
Q2 24
$-118.1M
$111.6M
Gross Margin
ASND
ASND
PB
PB
Q1 26
Q4 25
90.5%
Q3 25
89.5%
Q2 25
80.1%
Q1 25
82.6%
Q4 24
91.9%
Q3 24
80.6%
Q2 24
68.2%
Operating Margin
ASND
ASND
PB
PB
Q1 26
Q4 25
65.1%
Q3 25
5.1%
64.4%
Q2 25
-33.5%
64.3%
Q1 25
-103.2%
62.7%
Q4 24
62.0%
Q3 24
-167.3%
62.1%
Q2 24
-370.2%
55.2%
Net Margin
ASND
ASND
PB
PB
Q1 26
31.6%
Q4 25
50.9%
Q3 25
-28.5%
50.3%
Q2 25
-24.6%
50.5%
Q1 25
-93.7%
49.1%
Q4 24
48.6%
Q3 24
-171.5%
48.6%
Q2 24
-303.9%
43.1%
EPS (diluted)
ASND
ASND
PB
PB
Q1 26
$1.16
Q4 25
$1.48
Q3 25
$1.45
Q2 25
$1.42
Q1 25
$1.37
Q4 24
$1.36
Q3 24
$1.34
Q2 24
$1.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
PB
PB
Cash + ST InvestmentsLiquidity on hand
$665.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-175.8M
$8.2B
Total Assets
$1.4B
$43.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
PB
PB
Q1 26
Q4 25
$665.3M
Q3 25
$582.2M
Q2 25
$533.6M
Q1 25
$559.4M
Q4 24
$604.3M
Q3 24
$675.6M
Q2 24
$279.4M
Stockholders' Equity
ASND
ASND
PB
PB
Q1 26
$8.2B
Q4 25
$-175.8M
$7.6B
Q3 25
$-188.0M
$7.7B
Q2 25
$-202.6M
$7.6B
Q1 25
$-205.0M
$7.5B
Q4 24
$-114.2M
$7.4B
Q3 24
$-105.1M
$7.4B
Q2 24
$-346.8M
$7.3B
Total Assets
ASND
ASND
PB
PB
Q1 26
$43.6B
Q4 25
$1.4B
$38.5B
Q3 25
$1.2B
$38.3B
Q2 25
$1.2B
$38.4B
Q1 25
$1.1B
$38.8B
Q4 24
$1.3B
$39.6B
Q3 24
$1.2B
$40.1B
Q2 24
$819.0M
$39.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
PB
PB
Operating Cash FlowLast quarter
$58.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
PB
PB
Q1 26
Q4 25
$58.2M
$78.3M
Q3 25
$194.8M
Q2 25
$98.2M
Q1 25
$-15.5M
$178.2M
Q4 24
$-330.7M
$-205.8M
Q3 24
$274.6M
Q2 24
$216.5M
Free Cash Flow
ASND
ASND
PB
PB
Q1 26
Q4 25
$68.5M
Q3 25
$185.7M
Q2 25
$91.8M
Q1 25
$171.1M
Q4 24
$-210.7M
Q3 24
$270.2M
Q2 24
$211.8M
FCF Margin
ASND
ASND
PB
PB
Q1 26
Q4 25
24.9%
Q3 25
67.9%
Q2 25
34.3%
Q1 25
64.5%
Q4 24
-78.7%
Q3 24
103.3%
Q2 24
81.8%
Capex Intensity
ASND
ASND
PB
PB
Q1 26
Q4 25
3.6%
Q3 25
3.3%
Q2 25
2.4%
Q1 25
2.7%
Q4 24
1.8%
Q3 24
1.7%
Q2 24
1.8%
Cash Conversion
ASND
ASND
PB
PB
Q1 26
Q4 25
0.56×
Q3 25
1.42×
Q2 25
0.73×
Q1 25
1.37×
Q4 24
-1.58×
Q3 24
2.16×
Q2 24
1.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASND
ASND

Segment breakdown not available.

PB
PB

Net Interest Income$321.1M87%
Noninterest Income$46.5M13%

Related Comparisons